313 related articles for article (PubMed ID: 33573417)
1. RET fusions in non-small-cell lung cancer: an emerging target reshaping the treatment paradigm.
Saleh K; Khalife N; Felefly T
Future Oncol; 2021 Apr; 17(12):1445-1448. PubMed ID: 33573417
[No Abstract] [Full Text] [Related]
2. [Drug approval: Selpercatinib and pralsetinib - RET-altered non-small cell lung cancer].
Courtier B; Pierret T
Bull Cancer; 2021 Jun; 108(6):562-563. PubMed ID: 34023064
[No Abstract] [Full Text] [Related]
3. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
4. FDA Approves Pralsetinib for Treatment of Adults With Metastatic RET Fusion-Positive NSCLC.
Wright KM
Oncology (Williston Park); 2020 Oct; 34(10):406-406;431. PubMed ID: 33058106
[TBL] [Abstract][Full Text] [Related]
5. Pralsetinib: First Approval.
Markham A
Drugs; 2020 Nov; 80(17):1865-1870. PubMed ID: 33136236
[TBL] [Abstract][Full Text] [Related]
6. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress of Fusion Genes RET in Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Chen D; Li Y; Dai L; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):591-597. PubMed ID: 34120433
[TBL] [Abstract][Full Text] [Related]
9. Exposure-Response Relationships for Pralsetinib in Patients with RET-Altered Thyroid Cancer or RET Fusion-Positive Nonsmall Cell Lung Cancer.
Kassir N; McDougall D; Kuruvilla D; Kim S; Kumar S; Rahman A; Ruf T; Cheeti S; Ankrom W
J Clin Pharmacol; 2024 Jun; 64(6):685-696. PubMed ID: 38337106
[TBL] [Abstract][Full Text] [Related]
10. Extrapulmonary tuberculosis in patients with RET fusion-positive non-small cell lung cancer treated with pralsetinib: A Korean single-centre compassionate use experience.
Lee YP; Jeong BH; Eun Y; Kang CI; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Eur J Cancer; 2021 Dec; 159():167-173. PubMed ID: 34753013
[TBL] [Abstract][Full Text] [Related]
11. Precision Targeted Therapy with BLU-667 for
Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
[TBL] [Abstract][Full Text] [Related]
12. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract][Full Text] [Related]
13. Selective RET kinase inhibition for patients with RET-altered cancers.
Subbiah V; Velcheti V; Tuch BB; Ebata K; Busaidy NL; Cabanillas ME; Wirth LJ; Stock S; Smith S; Lauriault V; Corsi-Travali S; Henry D; Burkard M; Hamor R; Bouhana K; Winski S; Wallace RD; Hartley D; Rhodes S; Reddy M; Brandhuber BJ; Andrews S; Rothenberg SM; Drilon A
Ann Oncol; 2018 Aug; 29(8):1869-1876. PubMed ID: 29912274
[TBL] [Abstract][Full Text] [Related]
14. Clinical evidence and adverse event management update of patients with RET- rearranged advanced non-small-cell lung cancer (NSCLC) treated with pralsetinib.
Russo GL; Bironzo P; Bennati C; Bonanno L; Catino A; Metro G; Petrini I; Russano M; Passaro A
Crit Rev Oncol Hematol; 2024 Feb; 194():104243. PubMed ID: 38135019
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated
Solomon BJ; Zhou CC; Drilon A; Park K; Wolf J; Elamin Y; Davis HM; Soldatenkova V; Sashegyi A; Lin AB; Lin BK; F Loong HH; Novello S; Arriola E; Pérol M; Goto K; Santini FC
Future Oncol; 2021 Mar; 17(7):763-773. PubMed ID: 33150799
[TBL] [Abstract][Full Text] [Related]
16. Lengthy Progression-Free Survival and Intracranial Activity of Cabozantinib in Patients with Crizotinib and Ceritinib-Resistant ROS1-Positive Non-Small Cell Lung Cancer.
Sun TY; Niu X; Chakraborty A; Neal JW; Wakelee HA
J Thorac Oncol; 2019 Feb; 14(2):e21-e24. PubMed ID: 30217491
[No Abstract] [Full Text] [Related]
17. Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
Tsui DCC; Kavanagh BD; Honce JM; Rossi C; Patil T; Camidge DR
Clin Lung Cancer; 2022 Jan; 23(1):e5-e8. PubMed ID: 34246540
[No Abstract] [Full Text] [Related]
18. Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.
Saleh K; Felefly T; Khalife N; Kourie HR
Pharmacogenomics; 2021 Apr; 22(5):247-250. PubMed ID: 33754802
[No Abstract] [Full Text] [Related]
19. An early look at selective RET inhibitor resistance: new challenges and opportunities.
Lin JJ; Gainor JF
Br J Cancer; 2021 May; 124(11):1757-1758. PubMed ID: 33758332
[TBL] [Abstract][Full Text] [Related]
20. Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case Report.
Wang P; Matton L; Kebir F; Kerrou K; Dubois A; Lacave R; Cadranel J; Fallet V
Clin Lung Cancer; 2022 Dec; 23(8):e568-e572. PubMed ID: 36127251
[No Abstract] [Full Text] [Related]
[Next] [New Search]